Literature DB >> 14701797

The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency.

Valérie Wittamer1, Françoise Grégoire, Patrick Robberecht, Gilbert Vassart, David Communi, Marc Parmentier.   

Abstract

Chemerin is a novel protein identified as the natural ligand of ChemR23 (chemerinR), a previously orphan G protein-coupled receptor expressed in immature dendritic cells and macrophages. Chemerin is synthesized as a secreted precursor, prochemerin, which is poorly active, but converted into a full agonist of chemerinR by proteolytic removal of the last six amino acids. In the present work, we have synthesized a number of peptides derived from the C-terminal domain of human prochemerin and have investigated their functional properties as agonists or antagonists of human chemerinR. We found that the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR. Extension of this peptide at its N terminus did not increase the activity, whereas further truncations rapidly resulted in inactive compounds. The C-terminal end of the peptide appeared crucial for its activity, as addition of a single amino acid or removal of two amino acids modified the potency by four orders of magnitude. Alanine-scanning mutagenesis identified residues Tyr(149), Phe(150), Gly(152), Phe(154), and Phe(156) as the key positions for chemerinR activation. A modified peptide (YHSFFFPGQFAFS) was synthesized and iodinated, and a radioligand binding assay was established. It was found that the ability of the various peptides to activate the chemerin receptor was strictly correlated with their affinity in the binding assay. These results confirm that a precise C-terminal processing is required for the generation of a chemerinR agonist. The possibility to restrict a medium sized protein to a nonapeptide, while keeping a low nanomolar affinity for its receptor is unusual among G protein-coupled receptors ligands. The identification of these short bioactive peptides will considerably accelerate the pharmacological analysis of chemerin-chemerinR interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14701797     DOI: 10.1074/jbc.M313016200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  The antimicrobial activity of chemerin-derived peptide p4 requires oxidative conditions.

Authors:  Urszula Godlewska; Bernadetta Bilska; Aneta Zegar; Piotr Brzoza; Arkadiusz Borek; Krzysztof Murzyn; Oliwia Bochenska; Agnieszka Morytko; Patryk Kuleta; Andrzej Kozik; Elzbieta Pyza; Artur Osyczka; Brian A Zabel; Joanna Cichy
Journal:  J Biol Chem       Date:  2018-11-30       Impact factor: 5.157

2.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

3.  The genetic design of signaling cascades to record receptor activation.

Authors:  Gilad Barnea; Walter Strapps; Gilles Herrada; Yemiliya Berman; Jane Ong; Brian Kloss; Richard Axel; Kevin J Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-28       Impact factor: 11.205

4.  Chemerin receptor blockade improves vascular function in diabetic obese mice via redox-sensitive and Akt-dependent pathways.

Authors:  Karla Bianca Neves; Aurelie Nguyen Dinh Cat; Rheure Alves-Lopes; Katie Yates Harvey; Rafael Menezes da Costa; Nubia Souza Lobato; Augusto Cesar Montezano; Ana Maria de Oliveira; Rhian M Touyz; Rita C Tostes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-09-14       Impact factor: 4.733

Review 5.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

6.  CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.

Authors:  Marion Leick; Julie Catusse; Marie Follo; Robert J Nibbs; Tanja N Hartmann; Hendrik Veelken; Meike Burger
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

Review 7.  Proteolytic regulatory mechanism of chemerin bioactivity.

Authors:  Xiao-Yan Du; Lawrence L K Leung
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2009-12       Impact factor: 3.848

8.  The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Authors:  Stephanie W Watts; Emma S Darios; Adam E Mullick; Hannah Garver; Thomas L Saunders; Elizabeth D Hughes; Wanda E Filipiak; Michael G Zeidler; Nichole McMullen; Christopher J Sinal; Ramya K Kumar; David J Ferland; Gregory D Fink
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

9.  Epithelial cells in fetal intestine produce chemerin to recruit macrophages.

Authors:  Akhil Maheshwari; Ashish R Kurundkar; Sadiq S Shaik; David R Kelly; Yolanda Hartman; Wei Zhang; Reed Dimmitt; Shehzad Saeed; David A Randolph; Charles Aprahamian; Geeta Datta; Robin K Ohls
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-05-14       Impact factor: 4.052

10.  Development of a membrane-anchored chemerin receptor agonist as a novel modulator of allergic airway inflammation and neuropathic pain.

Authors:  Jamie R Doyle; Subrahmanian T Krishnaji; Guangli Zhu; Zhen-Zhong Xu; Daniel Heller; Ru-Rong Ji; Bruce D Levy; Krishna Kumar; Alan S Kopin
Journal:  J Biol Chem       Date:  2014-03-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.